KDB Silicon Valley

KDB Silicon Valley is the U.S.-based venture capital subsidiary of the Korea Development Bank (KDB), established in 2021 and headquartered in Mountain View, California. The firm focuses on early-stage and Series A investments in high-growth sectors, including biotechnology, life sciences, artificial intelligence, and robotics. KDB Silicon Valley serves as a strategic bridge for Korean startups entering the U.S. market and American companies expanding into Korea, providing both direct capital and access to a global venture network. Its portfolio includes innovative healthcare companies such as ImpriMed, which uses AI for personalized cancer treatment, and BreezeBio, a developer of mRNA delivery technologies. By leveraging the financial strength of its parent institution, the firm aims to foster a cross-border ecosystem for technological innovation and entrepreneurial growth.